Evidence map›Paper›PMID 41053651›Full record

ArticleBMC cancer2025

Novel anticancer effect of substituted imidazole derivatives against urothelial carcinoma: integrating In vitro screening and molecular docking for target kinases.

Basma Emad Aboulhoda, Abdelsattar M Omar, Sara Elfarrash, Mansour Abdullah Alghamdi, Ahmed A Emam, Randa El-Gamal, Soad E Abo-Elhoda, Mohamed F Zayed

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Basma Emad AboulhodaDepartment of Anatomy and Embryology, Faculty of Medicine, Cairo University, Cairo, Egypt. basma.emad@kasralainy.edu.eg.ORCID http://orcid.org/0000-0001-5582-7089
Abdelsattar M OmarDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Sara ElfarrashDepartment of Medical Physiology, Faculty of Medicine, Mansoura University, 35516, Mansoura, Egypt.
Mansour Abdullah AlghamdiCentral Labs, King Khalid University, P.O. Box 960, AlQura'a, Abha, Saudi Arabia.
Ahmed A EmamMedical Experimental Research Center (MERC), Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt.
Randa El-GamalMedical Experimental Research Center (MERC), Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt.
Soad E Abo-ElhodaPharmaceutical Chemistry Department, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt.
Mohamed F ZayedPharmaceutical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, 11884, Egypt.

Funding

Research Support Program for Central labs at King Khalid University CL/PRI/C/4
6 · The paper itself

Abstract

Four novel substituted imidazole derivatives-5a (Kim-161), 5b (Kim-111), 5c (Kim-261), and 5d (Kim-231) were evaluated for their antiproliferative activity against urothelial carcinoma. Among these, the two derivatives Kim-161 (5a) and Kim-111 (5b) demonstrated potent cytotoxicity against the T24 transitional carcinoma cell line, with IC

Indexed as

Antineoplastic AgentsCarcinoma, Transitional CellImidazolesProtein Kinase InhibitorsUrinary Bladder NeoplasmsApoptosisCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMolecular Docking SimulationSignal TransductionAntineoplastic AgentsImidazolesProtein Kinase InhibitorsAnti-cancerBladder cancerDesignDiscoveryImidazole, developmentSynthesis

Identifiers

PMID41053651
PMCPMC12502568

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.